CD19 and mantle cell lymphoma: A different bispecific CAR T cell product targeting CD-19 and CD-20 has been evaluated in r/r NHL with mantle cell lymphoma (MCL), DLBCL, and chronic lymphocytic leukemia (CLL) in two escalating doses in a phase 1 study [24].